|
|
|
|
|
|
|
|
|
|
"Targeting src kinase with combination of dasatinib and oxaliplatin may be an attractive approach in this disease."
Monday, July 11, 2011
Targeting Src in Mucinous Ovarian Carcinoma (dasatinib/oxaliplatin)
"Targeting src kinase with combination of dasatinib and oxaliplatin may be an attractive approach in this disease."
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.